| Target Price | $81.60 |
| Price | $78.63 |
| Potential |
3.78%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Pieris Pharmaceuticals, Inc. 2026 .
The average Pieris Pharmaceuticals, Inc. target price is $81.60.
This is
3.78%
register free of charge
$126.00
60.24%
register free of charge
$50.49
35.79%
register free of charge
|
|
| A rating was issued by 19 analysts: 18 Analysts recommend Pieris Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pieris Pharmaceuticals, Inc. stock has an average upside potential 2026 of
3.78%
register free of charge
|
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Oct 09 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Oct 02 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Sep 24 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Sep 09 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Oct 09 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Oct 02 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Sep 26 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 25 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Sep 24 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Sep 09 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 19 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


